The Virtus device aims to address the clinical need for patients with coexisting obstructive sleep apnea and teeth grinding during sleep. Key takeaways:SomnoMed commenced a controlled market release of Virtus in North America, Europe, and APAC for patients with OSA and coexisting sleep bruxism. Karen Borg assumed the role of sole CEO as Amrita Blickstead stepped down from the co-CEO position. SomnoMed Limited recently initiated a controlled market release of a new oral appliance in North America, Europe, and the Asia-Pacific region. Amrita Blickstead stepped down as co-CEO and executive director, effective July 27.